<?xml version='1.0' encoding='utf-8'?>
<document id="27533047"><sentence text="Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice."><entity charOffset="82-94" id="DDI-PubMed.27533047.s1.e0" text="itraconazole" /><entity charOffset="98-108" id="DDI-PubMed.27533047.s1.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.27533047.s1.e0" e2="DDI-PubMed.27533047.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27533047.s1.e0" e2="DDI-PubMed.27533047.s1.e1" /></sentence><sentence text="1" /><sentence text=" The aim of this study was to investigate the influence of itraconazole (ITCZ) on tacrolimus absorption, distribution and metabolism by developing a semi-physiological pharmacokinetic model of tacrolimus in mice"><entity charOffset="59-71" id="DDI-PubMed.27533047.s3.e0" text="itraconazole" /><entity charOffset="73-77" id="DDI-PubMed.27533047.s3.e1" text="ITCZ" /><entity charOffset="82-92" id="DDI-PubMed.27533047.s3.e2" text="tacrolimus" /><entity charOffset="193-203" id="DDI-PubMed.27533047.s3.e3" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e0" e2="DDI-PubMed.27533047.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e0" e2="DDI-PubMed.27533047.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e0" e2="DDI-PubMed.27533047.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e0" e2="DDI-PubMed.27533047.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e1" e2="DDI-PubMed.27533047.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e1" e2="DDI-PubMed.27533047.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e1" e2="DDI-PubMed.27533047.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e2" e2="DDI-PubMed.27533047.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27533047.s3.e2" e2="DDI-PubMed.27533047.s3.e3" /></sentence><sentence text=" 2" /><sentence text=" Mice were randomly divided into four groups, namely control group (CG, taking 3 mg kg-1 tacrolimus only), low-dose group (LDG, taking tacrolimus with 12"><entity charOffset="89-99" id="DDI-PubMed.27533047.s5.e0" text="tacrolimus" /><entity charOffset="135-145" id="DDI-PubMed.27533047.s5.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.27533047.s5.e0" e2="DDI-PubMed.27533047.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27533047.s5.e0" e2="DDI-PubMed.27533047.s5.e1" /></sentence><sentence text="5 mg kg-1 ITCZ), medium-dose group (MDG, taking tacrolimus with 25 mg kg-1 ITCZ) and high-dose group (HDG, taking tacrolimus with 50 mg kg-1 ITCZ)"><entity charOffset="48-58" id="DDI-PubMed.27533047.s6.e0" text="tacrolimus" /><entity charOffset="114-124" id="DDI-PubMed.27533047.s6.e1" text="tacrolimus" /><entity charOffset="10-19" id="DDI-PubMed.27533047.s6.e2" text="ITCZ" /><entity charOffset="75-84" id="DDI-PubMed.27533047.s6.e3" text="ITCZ" /><entity charOffset="141-150" id="DDI-PubMed.27533047.s6.e4" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e2" e2="DDI-PubMed.27533047.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e2" e2="DDI-PubMed.27533047.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e2" e2="DDI-PubMed.27533047.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e2" e2="DDI-PubMed.27533047.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e2" e2="DDI-PubMed.27533047.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e0" e2="DDI-PubMed.27533047.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e0" e2="DDI-PubMed.27533047.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e0" e2="DDI-PubMed.27533047.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e0" e2="DDI-PubMed.27533047.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e3" e2="DDI-PubMed.27533047.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e3" e2="DDI-PubMed.27533047.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e3" e2="DDI-PubMed.27533047.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e1" e2="DDI-PubMed.27533047.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27533047.s6.e1" e2="DDI-PubMed.27533047.s6.e4" /></sentence><sentence text=" 3" /><sentence text=" Liver clearance (CLli) decreased significantly (**p &lt; 0" /><sentence text="01) in LDG (35" /><sentence text="3%), MDG (45" /><sentence text="2%) and HDG (58" /><sentence text="7%) mice compared to CG mice" /><sentence text=" With respect to gut clearance (CLgu), significant (**p &lt; 0" /><sentence text="01) decrease was also revealed in LDG (35" /><sentence text="9%), MDG (50" /><sentence text="2%) and HDG (64" /><sentence text="6%) mice" /><sentence text=" A significant (**p &lt; 0" /><sentence text="01) higher tacrolimus brain-to-blood partition coefficient (Kt,br) was found in MDG (25" /><sentence text="3%) and HDG (55" /><sentence text="9%) mice than in CG mice" /><sentence text=" Moreover, a significant (*p &lt; 0" /><sentence text="05) increase (16" /><sentence text="3%) was found in the absorption rate constant (Ka) in HDG mice compared to CG mice" /><sentence text=" There was a significant (**p &lt; 0" /><sentence text="01) association between ITCZ dose and the change in CLgu (ΔCLgu, r= -0"><entity charOffset="24-27" id="DDI-PubMed.27533047.s26.e0" text="ITCZ" /></sentence><sentence text="790), the change in CLli (ΔCLli, r= -0" /><sentence text="787) and the change in Kt,br (ΔKt,br, r = 0" /><sentence text="727), while the association between ITCZ dose and the change in Ka (ΔKa) was not significant (p &gt; 0"><entity charOffset="36-39" id="DDI-PubMed.27533047.s29.e0" text="ITCZ" /></sentence><sentence text="05)" /><sentence text=" 4" /><sentence text=" These findings could be useful in predicting the efficacy and toxicity of tacrolimus, and drug-drug interaction of ITCZ and tarcolimus in human"><entity charOffset="75-85" id="DDI-PubMed.27533047.s32.e0" text="tacrolimus" /><entity charOffset="116-125" id="DDI-PubMed.27533047.s32.e1" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.27533047.s32.e0" e2="DDI-PubMed.27533047.s32.e0" /><pair ddi="false" e1="DDI-PubMed.27533047.s32.e0" e2="DDI-PubMed.27533047.s32.e1" /></sentence><sentence text="" /></document>